Acurex Biosciences to Present at the Michael J. Fox Foundation Parkinson's Disease Therapeutics Conference

Acurex Biosciences Corporation, a privately-held biopharmaceutical company with a mission to stop neurodegeneration before it starts, has been selected to present at the 15^th annual Parkinson's Disease Therapeutics Conference hosted by the Michael J. Fox Foundation.

Presentation Highlights:
"De-risking Therapeutic Development: The Power of Mitophagy Biomarkers in PD"
Speaker: William Shrader, Ph.D., Co-founder and CEO of Acurex Biosciences
Venue: Quorum by Convene Center, New York, NY
Date & Time: October 19^th, 2023, at 1:30 p.m. ET

The Parkinson's Disease Therapeutics Conference is the Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. Each year, the PD Therapeutics Conference brings together 300 research and business development professionals from academia and industry, showcasing the most exciting and innovative research from MJFF's research portfolio. Speaker presentations and poster sessions highlight novel advances in basic and translational research from both academic and industry labs. The event is a platform for field leaders to share new and unpublished results and to foster new relationships and collaborations.

About Acurex Biosciences

Acurex is focused on putting an end to the devastating effects of neurodegenerative diseases, starting with Parkinson's disease (PD). Such disorders represent a rapidly growing unmet medical need and the primary cause of adult disability worldwide. PD is the second largest and fastest-growing neurodegenerative disease, yet there are currently no drugs that effectively address its symptoms or slow its progression. In 2019, Acurex was founded following a significant discovery at Stanford University around mitophagy, the process of removing damaged mitochondria from cells. With exclusive rights to this intellectual property, Acurex has created a drug discovery platform that identifies novel targets responsible for mitophagy defects in neurodegenerative disease. Using biomarker-guided drug development, Acurex is poised to fundamentally change the PD landscape and pioneer the future of personalized medicine in the treatment of neurodegeneration.

Acurex has secured over $18M in private and grant seed funding, including funds from Stanford University, the Silverstein Foundation, the Michael J. Fox Foundation, and the NIH. Acurex is raising its Series A to fund the continued development of its therapeutic and biomarker programs and to conduct its first human clinical trials. The Acurex team is led by veteran scientists with a proven track record in CNS drug development and serial life sciences entrepreneurs. For more information, please visit https://www.acurex.com.